A new paper by an international group of researchers from several different centers has maybe identified a new way to differentiate accurately between indolent and aggressive forms of prostate cancer at time of initial diagnosis. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: aggressive, expression, EZH2, gene, indolent, risk, TOP2A | 1 Comment »
According to an article published in Science on Friday last week, activation of an epigenetic regulator known as EZH2 (“enhancer of zeste homolog 2”) may be critical to the onset and progression of castration-resistant prostate cancer (CRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer | Tagged: castration-resistant, CRPC, epigenetics, EZH2 | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 